SYHX1901, an oral dual JAK/SYK inhibitor, for moderate-to-severe plaque psoriasis: a randomized phase 2 trial Journal of the American Academy of Dermatology
Published: 30 September 2025| Version 1 | DOI: 10.17632/bwsg339674.1
Contributor:
超 刘Description
This dataset includes supplementary materials for the Phase 2 clinical trial report on SYHX1901 for plaque psoriasis (JAAD)
Files
Categories
Randomized Controlled Trial, Psoriasis